Shkreli appearing before U.S. lawmakers, pleading the Fifth

WASHINGTON -- Pharmaceutical chief Martin Shkreli refused to testify Thursday in an appearance before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired.

See Full Article

Shkreli, widely scorned for hiking the price of a long-established and potentially lifesaving drug by more than 5,000 per cent, exercised his Fifth Amendment right against self-incrimination when he went before the House Oversight and Government Reform Committee.

Rep. Elijah Cummings, the top Democrat on the panel, berated Shkreli: "I call this money blood money ... coming out of the pockets of hardworking Americans," he said.

The 32-year-old Shkreli faces separate criminal charges of securities fraud in connection with another drug company he owned.

The lawmakers summoned him to answer for the decision that made him infamous: raising the price for Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection.

The brash entrepreneur and former hedge fund manager, who pleaded not guilty after his arrest in December in New York, has been out on $5 million bail. He walked into the packed hearing room well before the session began and met the crush of cameras. Even a few members of the House panel were swept up in the curiosity and snapped Shkreli's photo on their cellphones. He wore a sport jacket and button-down shirt, conservatively preppie attire.

Also appearing before the lawmakers is Turing's chief commercial officer and the interim CEO of Canada's largest drugmaker, Valeant Pharmaceuticals. Documents from Valeant and Turing show they have made a practice of buying and then dramatically raising prices for, low-cost drugs given to patients with life-threatening conditions including heart disease, AIDS and cancer, according to excerpts released this week by the House panel.

The two companies' executives argue that commitment is to ensuring that cost isn't a deterrent for patients who need the drugs.

Documents show how executives at both companies planned to maximize profits while fending off negative publicity over the price hikes.

Presentations by Turing executives, part of the trove of documents, show that as early as last May, the company planned to turn Daraprim into a $200-million-a-year drug by dramatically increasing its price. Turing bought the 60-year-old drug from Impax Laboratories in August for $55 million and swiftly raised its price.

Shkreli said in an email to one contact: "We raised the price from $1,700 per bottle to $75,000. Should be a very handsome investment for all of us."

But anticipating a possible backlash, the company warned in an internal memo that advocates for HIV patients might react to the price hike.

Valeant likewise identified revenue goals first and then used drug prices to reach them, committee staff said in a memo. It said Valeant believed it could repeatedly raise the prices of Nitropress and Isuprel without repercussions because they're administered by hospitals, which are less price-sensitive than consumers.

Valeant used patient assistance programs to distract attention and justify its price hikes, according to the memo.



Advertisements

Latest Economic News

  • No desk of your own: The office plan of the future?

    Economic CBC News
    Imagine coming to work every day and not being sure where to sit. You don't have a desk — instead, you need to figure out what's ahead in your day and what type of space you need, and then find a spot. Source
  • Is your condo board above board? Tips for evaluating condo governance

    Economic CBC News
    Condominium governance is in the spotlight after an investigation by CBC Toronto reporters unveiled questionable practices at a series of downtown Toronto buildings. Owners and property managers in those buildings say a group of people have aggressively sought control of the boards and budgets of multiple condos. Source
  • Hong Kong cops arrest 21 Uber drivers in latest crackdown

    Economic CTV News
    Hong Kong police launched a fresh crackdown Tuesday on Uber, arresting 21 drivers suspected of working for the ride-hailing giant in the Asian financial centre. It's the latest regulatory headache for Uber, which already is fighting a similar case in Hong Kong. Source
  • Asian stocks drift in wake of Manchester blast

    Economic CTV News
    TOKYO - Asian shares were mostly higher in early trading Tuesday after police said they were treating an explosion in Manchester, England, that killed at least 19 people as a terror attack. Oil prices fell back after Monday's rally. Source
  • Sony boss promises profitability but quiet on specifics

    Economic CTV News
    TOKYO -- Sony’s leader promised a comeback for the Japanese electronics and entertainment company having its best profitability in two decades. “We are a company that moves people,” said Chief Executive Kazuo Hirai, as he outlined the strategy for the company at its Tokyo headquarters Tuesday. Source
  • CRA says eight agency workers fired for roles in privacy breaches

    Economic CTV News
    OTTAWA -- The Canada Revenue Agency says eight of its employees were fired in the last fiscal year after violating taxpayers' privacy. Previously, the agency has not always confirmed if an employee was fired or shuffled out of the CRA for being part of a privacy breach, often citing the employee's privacy. Source
  • 2 more leaks found along Dakota Access pipeline

    Economic CTV News
    BISMARCK, N.D. -- The Dakota Access pipeline system leaked more than 100 gallons of oil in North Dakota in two separate incidents in March -- the second and third known leaks discovered as crews prepared the disputed $3.8 billion pipeline for operation. Source
  • Leaks found on Dakota Access pipeline system

    Economic CTV News
    BISMARCK, N.D. -- The Dakota Access pipeline and a feeder line leaked more than 100 gallons of oil in North Dakota in separate incidents in March as crews prepared the disputed $3.8 billion pipeline for operation. Source
  • Philippe Couillard says Quebec needs to take care of Bombardier

    Economic CTV News
    HAIFA, Israel -- Quebec's premier says the province needs to take care of Bombardier because of its unique importance to the province. Philippe Couillard is urging Quebecers to support the transportation company, which has recently faced a strong public backlash over planned hikes to executive pay. Source
  • Canadian banks set to reveal 1st earnings since CBC coverage on sales practices

    Economic CBC News
    The Canadian banks are expected to benefit from rising U.S. interest rates and fewer bad loans in the oilpatch as they start reporting their latest quarterly results this week, but analysts say worries about the housing market and consumer debt remain key concerns. Source